Tabalumab
Tabalumab (pronounced ta-BAL-u-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases and cancer. It was developed by Eli Lilly and Company, a global pharmaceutical company.
Pronunciation
The pronunciation of Tabalumab is ta-BAL-u-mab.
Etymology
The name "Tabalumab" follows the World Health Organization's guidelines for the International Nonproprietary Names (INN) of monoclonal antibodies. The suffix "-mab" is used for all these types of antibodies, while the infix "-l-" indicates that the drug is a immunomodulator, and the prefix "Taba-" does not carry a specific meaning.
Indications
Tabalumab was primarily developed for the treatment of autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. It was also investigated for potential use in the treatment of various types of cancer.
Mechanism of Action
Tabalumab works by targeting and inhibiting the B-cell activating factor (BAFF), a protein that promotes the survival and growth of B cells. By blocking BAFF, Tabalumab reduces the number of harmful B cells, thereby reducing inflammation and damage to healthy tissues.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Cancer
- Rheumatoid arthritis
- Systemic lupus erythematosus
- B-cell activating factor
- Immunomodulator
See Also
External links
- Medical encyclopedia article on Tabalumab
- Wikipedia's article - Tabalumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski